Compare · MYMD vs NEOG
MYMD vs NEOG
Side-by-side comparison of MyMD Pharmaceuticals Inc. (MYMD) and Neogen Corporation (NEOG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MYMD and NEOG operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NEOG is the larger of the two at $2.00B, about 13.4x MYMD ($149.1M).
- NEOG has hit the wire 3 times in the past 4 weeks while MYMD has been quiet.
- NEOG has more recent analyst coverage (5 ratings vs 0 for MYMD).
- Company
- MyMD Pharmaceuticals Inc.
- Neogen Corporation
- Price
- -
- -
- Market cap
- $149.1M
- $2.00B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 1989
- News (4w)
- 0
- 3
- Recent ratings
- 0
- 5
MyMD Pharmaceuticals Inc.
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, engages in the development of drug candidates to treat autoimmune, and aging and age-related diseases. It is developing MYMD-1, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel diseases, as well as to treat age-related illnesses such as, frailty and sarcopenia. The company is also developing Supera-CBD, a synthetic preclinical cannabidiol derivative that targets CB2 receptors. The company is based in Baltimore, Maryland.
Neogen Corporation
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.
Latest MYMD
- TNF Pharmaceuticals Trades Under New Ticker "TNFA"
- TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol "TNFA" Effective Before Market Open Today
- MyMD Pharmaceuticals Announces Corporate Rebranding To New Name TNF Pharmaceuticals, To Begin Under The New Trading Symbol "TNFA" Effective July 24, 2024
- MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.
- SEC Form DEF 14A filed by MyMD Pharmaceuticals Inc.
- SEC Form 3 filed by new insider Friscia Stephen
- Latest Key Hires & Board Changes In Cannabis Industry: Canopy Growth, Acreage And More
- MyMD Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form S-3 filed by MyMD Pharmaceuticals Inc.
- Amendment: MyMD Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
Latest NEOG
- Chief Accounting Officer Moylan John Patrick covered exercise/tax liability with 2,553 units of Restricted Stock Units, decreasing direct ownership by 10% to 23,571 units (SEC Form 4)
- SEC Form SD filed by Neogen Corporation
- Former Chief Legal Officer Rocklin Amy M exercised 35,183 shares at a strike of $9.29 and covered exercise/tax liability with 10,241 shares, increasing direct ownership by 44% to 82,182 units (SEC Form 4)
- Chief Accounting Officer Moylan John Patrick exercised 4,558 shares at a strike of $9.53 and covered exercise/tax liability with 1,568 shares, increasing direct ownership by 21% to 17,337 units (SEC Form 4)
- Chief Legal Officer Stacey Jennifer Evans was granted 39,349 shares (SEC Form 4)
- Neogen's Listeria Right Now™ Test Receives AOAC® Performance Tested Methods℠ Certification
- Neogen Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 3 filed by new insider Stacey Jennifer Evans
- SEC Form 10-Q filed by Neogen Corporation
- Neogen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits